Pradaxa Maker Working On Antidote Amid Rise In Lawsuits

Dallas, TX (PRWEB) November 29, 2012

German drug maker Boehringer Ingelheim announced this month that they are now working to develop an antidote that will slow internal bleeding in emergency situations.*

The announcement comes as the latest report from the Judicial Panel on MultiDistrict Litigation on November 14, 2012 shows the number of Pradaxa internal bleeding cases has increased 50% since September 5th.*

According to USA Today on August 19, 2012, Pradaxa led all other medications in 2011 with reports of 3,781 side effects and 542 deaths to the FDA.

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

On October 3, 2012, the Institute for Safe Medicine Practices QuarterWatch (PDF) estimated that prescription drug complaints to the FDA have risen 90% in the past 4 years, and two drugs, Pradaxa and Chantix, are responsible for 37% of that increase.

While all anticoagulants can cause internal bleeding, the Journal of Neurosurgery reported doctors concerns on March 6, 2012 that, once Pradaxa causes internal bleeding, there is currently no antidote to stop it.

Due to the number of Pradaxa lawsuits filed, a central federal court has been established in Illinois. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa warnings, or to speak with a lawyer, visit http://www.DrugRisk.com.

Read more here:
Pradaxa Maker Working On Antidote Amid Rise In Lawsuits